Fluorescence Imaging of IBD and RA Using Adalimumab-800CW

Phase 1

Not yet recruiting

• Conditions: IBD; Rheumatoid Arthritis
• Interventions: Drug: Adalimumab-800CW; Device: Fluorescence Imaging

• Registration Number: NCT03938701
• Lead Sponsor: University Medical Center Groningen

Brief Summary

Inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) are both auto-immune diseases that are characterized by chronic relapsing inflammation of respectively the ileocolonic tissue and the synovium. Pathogenesis of both auto-immune diseases is attributed to the proinflammatory cytokine tumor necrosis factor α (TNFa). Adalimumab is a human monoclonal anti-TNF antibody used for treating patients with moderate to severely active IBD and RA. However, current rates of therapeutic nonresponsiveness to this antibody are variable and difficult to predict in advance, whereas patients are potentially exposed to a non-effective treatment and its potential side effects; while clinical deterioration progresses. A key unmet need is the development of a predictive tool for assessment of a therapeutic (non-) response to patients and finding an optimal dose strategy in individual patients before initiating anti-TNF therapy. Unfortunately, we currently lack crucial information about drug distribution of the drug of interest throughout the targeted inflamed tissue itself. Therefore, it remains unknown in both IBD and RA, if the drug reaches its target (in sufficient amounts) and how local drug concentrations are related to therapeutic response. Thus, we linked adalimumab to a fluorescent dye (adalimumab-800CW) in order to create a fluorescent signal of the labelled drug in the diseased tissue that we can visualize and quantify with dedicated optical fluorescence imaging systems. We hypothesize that this tracer will bind to TNFa in the mucosa/synovium and thus create a map of medicine distribution in vivo due to colocalization of the fluorescent labelled compound. Therefore, the aim of this study is to assess the feasibility of fluorescent molecular imaging of adalimumab-800CW in IBD and RA patients.

Detailed Description

See brief summary

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2019-02-25
• Study First Submitted QC: 2019-05-03
• Study First Posted: 2019-05-06
• Status Verified: 2022-05
• Last Update Submitted: 2023-05-02
• Last Update Posted: 2023-05-06
• Study Start: 2023-06
• Primary Completion: 2024-06
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Fluorescence imaging of RA with adalimumab-800CW	Fluorescence Imaging	Fluorescence imaging with adalimumab-800CW in rheumatoid arthritis (RA). A non-randomised, non-blinded, prospective, feasibility study. Administration of 4.5 mg, 15 mg or 25 mg of adalimumab-800CW in 15 patients.
Fluorescence imaging of RA with adalimumab-800CW	Adalimumab-800CW	Fluorescence imaging with adalimumab-800CW in rheumatoid arthritis (RA). A non-randomised, non-blinded, prospective, feasibility study. Administration of 4.5 mg, 15 mg or 25 mg of adalimumab-800CW in 15 patients.
Fluorescence imaging of IBD with adalimumab-800CW	Adalimumab-800CW	Fluorescence imaging with adalimumab-800CW in inflammatory bowel disease (IBD). A non-randomised, non-blinded, prospective, feasibility study. Administration of 4.5 mg, 15 mg or 25 mg of adalimumab-800CW in 15 patients.
Fluorescence imaging of IBD with adalimumab-800CW	Fluorescence Imaging	Fluorescence imaging with adalimumab-800CW in inflammatory bowel disease (IBD). A non-randomised, non-blinded, prospective, feasibility study. Administration of 4.5 mg, 15 mg or 25 mg of adalimumab-800CW in 15 patients.

Primary Outcome Measures

Name	Time	Method
Discrimination of inflamed and normal tissue based on in vivo and ex vivo fluorescence measurements from adalimumab-800CW gained during fluorescence endoscopy in patients with Crohn's disease (CD).	Up to 1 year	The target-to-background/contrast-to-noise ratio will be calculated after fluorescence molecular endoscopy (FME) and MDSFR/SFF spectroscopy. These results will be related to the gold standard clinical care to evaluate the feasibility of fluorescence molecular endoscopy using the tracer adalimumab-800CW for the evaluation of drug distribution in patients with Crohn's disease.
Safety: number of participants with symptoms or changes in vital signs (blood pressure, heart rate and temperature) that are related to administration of adalimumab-800CW	Up to 30 minutes after stop tracer injection	To determine the safety of adalimumab-800CW in inflammatory bowel disease (IBD) and rheumatoid arthritis patients by monitoring of vital signs (blood pressure, heart rate and temperature) before, during and after tracer infusion.; These vital signs are measured before tracer administration, directly after and then every 15 minutes until 1 hour after tracer administration.
Discrimination of inflamed and normal tissue based on in vivo fluorescence measurements from adalimumab-800CW gained during fluorescence imaging of the hand of rheumatoid arthritis patients	Up to 1 year	The target-to-background/contrast-to-noise ratio will be calculated after fluorescence imaging. These results will be related to the gold standard clinical care to evaluate the feasibility of molecular fluorescence imaging using the tracer adalimumab-800CW for the evaluation of drug distribution in patients with rheumatoid arthritis.
Discrimination of inflamed and normal tissue based on in vivo and ex vivo fluorescence measurements from adalimumab-800CW gained during fluorescence endoscopy in patients with ulcerative colitis (UC).	Up to 1 year	The target-to-background/contrast-to-noise ratio will be calculated after fluorescence molecular endoscopy (FME) and MDSFR/SFF spectroscopy. These results will be related to the gold standard clinical care to evaluate the feasibility of fluorescence molecular endoscopy using the tracer adalimumab-800CW for the evaluation of drug distribution in patients with ulcerative colitis.
Safety: number of participants with (serious) adverse events that are related to the administration of adalimumab-800CW	Up to 24 hours after tracer injection	(serious) adverse events will be monitored until 24 hours after tracer administration.

Secondary Outcome Measures

Name	Time	Method
The correlation between the fluorescence intensity and the disease activity measured with the DAS28 in patients with RA.	Up to 1 year	The DAS28 (Disease Activity Score 28) is developed and validated by the EULAR (European League Against Rheumatism) to measure the progress and improvement of Rheumatoid Arthritis by measuring 28 joints. When looking at these joints, both the number of joints with tenderness upon touching and swelling are counted. Furthermore, the erythrocyte sedimentation rate is measured and a patients assessment of disease activity during the preceding 7 days is measured on a scale between 0 and 100, where 0 is 'no activity' and 100 is 'highest activity possible'.; DAS28 values range from 0.49 to 9.07 while higher values mean a higher disease activity. A DAS28 below the value of 2.6 is interpreted as Remission. Between 2.6 and 3.2 as low disease activity, and between 3.2 and 5.1 as moderate. Above 5.1 is indicated as high disease activity.
The correlation between fluorescence intensity and the clinical disease activity score in ulcerative colitis using the SCCAI;	Up to 1 year	The SCCAI is a diagnostic questionnaire to assess the severity of symptoms in patients with ulcerative colitis. The score ranges from 0 to 19 based on questions on topics regarding the bowel frequency, urgency of defecation, blood in stool and general health. A score of 5 or higher indicates active disease.
Quantification of fluorescence signals in vivo and ex vivo of inflamed and normal tissue using multi-diameter single-fiber reflectance, single-fiber fluorescence (MDSFR/SFF) spectroscopy measurements in IBD patients;	Up to 1 year	The measurements with MDSFR/SFF are performed on the same tissue: in vivo during endoscopy and ex vivo on the biopsies. Therefore they are considered as one measurement outcome.; Measurements are taken from both normal tissue and inflammation tissue.
Calculation of optical properties with MDSFR/SFF spectroscopy in patients with RA	Up to 1 year	To quantify the optical properties, in vivo using multi-diameter single-fiber reflectance, single-fiber fluorescence (MDSFR/SFF) spectroscopy measurements;
Correlation in IBD between the detected fluorescence signals in vivo and the clinical response to induction therapy at week 14.	Up to 1 year	Values of clinical disease activity scores (SCCAI for UC and CDAI for CD) will be obtained at week 14 from the patient's electronic medical chart in order to determine the correlation with the target-to-background ratio measured at baseline during fluorescence molecular endoscopy (FME) and MDSFR/SFF spectroscopy.
The correlation between fluorescence intensity and the clinical disease activity score in Crohn's disease using the Crohn's Disease Activity Index (CDAI).	Up to 1 year	The CDAI quantifies the symptoms of patients with CD. The index consists of 8 factors, each summed after adjustment with a weighting factor. Symptoms are scored over the last 7 days and include: number of soft/liquid stools, general well being, severity of abdominal pain, number of complications, ant-diarrhea drug use, abdominal mass, hematocrit, body weight.; Remission is defined as CDAI \< 150 and severe disease as CDAI \> 450.
The correlation between fluorescence intensity and the endoscopic disease activity score in ulcerative colitis using the Mayo endoscopic subscore;	Up to 1 year	The endoscopic Mayo Score (Mayo endoscopic subscore) evaluates ulcerative colitis stage, based only on endoscopic exploration. Endoscopic activity is based upon the assessment of a few features, such as the presence of erythema, visibility of the vascular pattern, friability, erosions, spontaneous bleeding and (large) ulcerations. Each score indicates endoscopic activity: 0 = inactive disease tot 3 = severely active disease.; 3-5 = mild activity 6-10 = moderate activity \>10 = severe activity
The correlation between fluorescence intensity and the disease activity score in Crohn's disease using the SES-CD score	Up to 1 year	SES-CD (Simple Endoscopic Score for Crohn Disease) is a endoscopic assessment tool for patients with Crohn's disease. Four parameters are evaluated: ulcers, surface involved by disease, surface involved by ulcerations and narrowings.; 0-2 = remission 3-6 = mild endoscopic activity 7-15 = moderate endoscopic activity \>15 = severe endoscopic activity
The correlation and validation of fluorescence signals detected in vivo to the pathology of biopsies for IBD patients;	Up to 1 year	Pathology findings are correlated to fluorescence signals to determine if pathology results (inflammation) correspond to fluorescence signals (high fluorescence) and vice versa, normal tissue corresponds too low fluorescence signals.

Trial Locations

Locations (1)

University Medical Center Groningen; 🇳🇱 Groningen, Netherlands